Neurocrine Biosciences Inc vs Nutrien Ltd — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Nutrien Ltd trades at $66.8 (market cap $31.67B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays a 3.3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | NTR | |
|---|---|---|
Market Cap | $17.40B | $31.67B |
Sector | Health | Basic Materials |
52-Week High | $180.55 | $83.94 |
52-Week Low | $123.10 | $53.64 |
Enterprise Value | $16.49B | $44.84B |
Dividend Yield | — | 3.3% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →